Dallas, TX: SandlerResearch announce Venezuela Pharmaceuticals and Healthcare Report Q4 2010
Original Source : Venezuela Pharmaceutical Market
http://www.sandlerresearch.org/reports/37158-venezuela-pharmaceuticals-and-healthcare-report-q4-2010.html
Buy Now : Market Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pipeline-analysis-and-mark.html
BMI forecasts a 3.8% year-on-year (y-o-y) contraction in Venezuelan real GDP for 2010, however, contrary to consensus we believe the worst of the recession has passed. Although the consumption and net export outlook remains weak, an uptick in government consumption and investment from China is likely to help push the economy towards our above-consensus projection of 3.2% y-o-y growth in 2011. Our Q410 Business Environment Ratings for the Americas continue to show that Venezuela’s pharmaceutical market is one of the most challenging in the region. Venezuela finds itself with the third lowest overall rating as the operating environment for drugmakers remains suboptimal due to weak intellectual property laws and a political regime that regularly speaks out against private enterprise. On a global scale, Venezuela has dropped in BMI’s Business Environment Ratings from 76th to 77th out of the 83 countries surveyed this quarter.
On the other hand, the structure of the country, with its fast growing urban population, creates an environment in which strong returns can be achieved, particularly in the generic drug sector. A rapidly growing population and the support for government funded healthcare programmes such as Barrio Adentro suggest positive long-term prospects.
This potential has not escaped the attention of some pharmaceutical companies that are seeking a low-cost base for entry and expansion in Latin America. In particular, mid-cap Indian generic drugmakers such as Glenmark Pharmaceuticals, Natco Pharma and JB Chemicals & Pharmaceuticals have expressed their intention to expand into the Venezuelan market. However, competition in the sector is likely to intensify, as South American drugmakers such as El Grupo Chemo and Eurofarma are already stepping up their presence in Venezuela.
BMI believes the Venezuelan government is likely to continue its policy to promote local pharmaceutical manufacturing to meet internal demand as much as possible, particularly after the recent diplomatic dispute between Venezuela and Colombia that has caused the collapse of the bilateral trade agreement between the two countries, valued at US$7bn per year. Other factors encouraging local manufacturing are the high levels of inflation and the forecast devaluation of the bolívar, which makes imported drugs increasingly less affordable.
The Venezuelan generic drug market was valued at VEB2.33bn (US$1.09bn) in 2009, accounting for 31.3% of the total market. By 2014, the market for generic medicines is expected to reach a value of VEB11.93bn (U$1.19bn), equating to a 38.58% compound annual growth rate (CAGR) in local currency terms or 1.81% in US dollar terms. In 2014, we anticipate that generics will account for 41.8% of the total market in terms of value, rising to 54.7% in 2019.
In contrast, revenue for patented drugs is expected to significantly decline over the next 10 years, reaching US$1.1bn by 2014 and contracting further to US$816mn by 2019, mainly due to high inflation and weakening consumer power. With this in mind, large multinational drugmakers will remain cautious over investments in Venezuela in the short and medium term.
Browse complete Report at : http://www.sandlerresearch.org/reports/37158-venezuela-pharmaceuticals-and-healthcare-report-q4-2010.html
Table Of Contents
Executive Summary 5
SWOT Analysis 7
Venezuela Pharmaceuticals And Healthcare Industry SWOT Analysis 7
Venezuela Political SWOT 8
Venezuela Economic SWOT 9
Venezuela Business Environment SWOT 9
Pharmaceutical Business Environment Ratings 10
Table: Americas Pharmaceutical Business Environment Ratings, Q410 10
Rewards 11
Risks 11
Venezuela – Market Summary 13
Regulatory Regime 14
Other Regulatory Issues 14
Intellectual Property Environment 14
IP Shortcomings 16
International Collaboration 17
Counterfeit Drugs 20
Pricing And Reimbursement 20
Industry Developments 23
Epidemiology 23
Communicable Diseases 23
Non-Communicable Diseases 26
Healthcare Sector 27
Healthcare Sector Developments 29
Hospital Sector 29
Private Healthcare Sector 30
Regional Healthcare Collaboration 31
Retail Pharmacy 32
Medical Devices 33
Industry Forecast Scenario 34
Overall Market Forecast 34
Key Growth Factors – Industry 36
Key Growth Factors – Macroeconomic 37
Table: Venezuela Economic Activity, 2007-2014 39
Prescription Drug Market Forecast 40
Patented Product Market Forecast 41
Generic Drug Market Forecast 42
OTC Medicine Market Forecast 44
Medical Device Market Forecast 46
Pharmaceutical Trade Forecast 47
Other Healthcare Data Forecasts 49
Key Risks To BMI’s Forecast Scenario 49
Competitive Landscape 52
Pharmaceutical Sector 52
Company Activity 53
OTC Medicines 55
Company Profiles 57
Indigenous Company Profiles 57
Grupo Farma 57
Elmor 59
Strides Latina (Sumifarma) 61
Calox International 62
Leading Multinationals 63
Pfizer 63
Sanofi-Aventis 66
GlaxoSmithKline 67
Boehringer Inglelheim 68
Novartis 69
Merck & Co 70
Country Snapshot: Venezuela Demographic Data 72
Section 1: Population 72
Table: Demographic Indicators, 2005-2030 72
Table: Rural/Urban Breakdown, 2005-2030 73
Section 2: Education And Healthcare 73
Table: Education, 2002-2005 73
Table: Vital Statistics, 2005-2030 73
ABBREVIATIONS
Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/
Browse all : Business Monitor International
http://www.sandlerresearch.org/publishers/business-monitor-international/
Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx
Related Reports:
Venezuela Pharmaceuticals and Healthcare Report Q3 2010
http://www.sandlerresearch.org/Reports/26548-venezuela-pharmaceuticals-and-healthcare-report-q3-2010.html
Venezuela Pharmaceuticals and Healthcare Report Q2 2010
http://www.sandlerresearch.org/Reports/21636-venezuela-pharmaceuticals-and-healthcare-report-q2-2010.html
United Kingdom Pharmaceuticals and Healthcare Report Q4 2010
http://www.sandlerresearch.org/Reports/37156-united-kingdom-pharmaceuticals-and-healthcare-report-q4-2010.html
Czech Republic Pharmaceuticals and Healthcare Report Q4 2010
http://www.sandlerresearch.org/Reports/37101-czech-republic-pharmaceuticals-and-healthcare-report-q4-2010.html
Cambodia Pharmaceuticals and Healthcare Report Q4 2010
http://www.sandlerresearch.org/Reports/37093-cambodia-pharmaceuticals-and-healthcare-report-q4-2010.html
About Us:
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.
We also provide 24/7 online and offline support to our customers
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/
